Streetbeat News

Analyst Ratings

VCNX

Vaccinex, Inc. (NASDAQ:VCNX) will present findings from two Phase 2 studies of its lead product, pepinemab, at the Society for Immunotherapy of Cancer's Annual Meeting. The studies show pepinemab's ability to induce the formation of lymphoid structures in tumors, improving outcomes to immune checkpoint inhibitors. In one study, pepinemab combined with Merck's KEYTRUDA doubled objective responses and progression free survival in patients with hard-to-treat tumors. Another study with Emory University showed pepinemab, combined with nivolumab and/or ipilimumab, prevented tumor recurrence for over 2 years in patients.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:13 pm

TSXV:BRVO

BMO Capital analyst Raj Ray has maintained an 'Outperform' rating on Bravo Mining, but has lowered the price target from C$5.5 to C$5.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:12 pm

GLW

MRK

TXN

VRTV

Jim Cramer, on CNBC’s 'Mad Money Lightning Round', gave his views on several stocks. He mentioned that Corning Incorporated had a disappointing quarter with no immediate bounce expected. He recommended buying Vertiv Holdings Co and holding onto Texas Instruments Incorporated despite a poor last quarter. He also noted that Merck & Co., Inc. is doing very well.

Portfolio Pulse from Lisa Levin

October 31, 2023 | 1:12 pm

HOWL

Werewolf Therapeutics (NASDAQ:HOWL) will present interim clinical results from its ongoing Phase 1/1b study of WTX-124 at the Society for Immunotherapy of Cancer's 38th Annual Meeting. The data will provide early insight into the safety and antitumor activity of WTX-124. The company will also present data supporting the potential of its PREDATOR platform and INDUKINE product candidates. A conference call and webcast to review the initial clinical results will be held on November 3, 2023.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:11 pm

XPO

BMO Capital analyst Fadi Chamoun maintains an 'Outperform' rating on XPO Logistics (NYSE:XPO) and has raised the price target from $87 to $100.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:10 pm

TREX

BMO Capital analyst Ketan Mamtora maintains a Market Perform rating on Trex Co (NYSE:TREX) and raises the price target from $70 to $72.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:09 pm

TSX:GEI

BMO Capital analyst Ben Pham has maintained a 'Market Perform' rating on Gibson Energy and raised the price target from C$22 to C$22.5.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:07 pm

OCUL

AffaMed Therapeutics announced positive top-line results from a real-world study in China evaluating the safety and efficacy of DEXTENZA in patients after cataract surgery. The trial met its primary and secondary endpoints, demonstrating a significant reduction of ocular inflammation and pain. AffaMed has a licensing agreement with Ocular Therapeutix, Inc. (NASDAQ: OCUL) for the development and commercialization of DEXTENZA in Greater China, South Korea, and certain ASEAN markets.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:07 pm

CHKP

BMO Capital analyst Keith Bachman maintains a Market Perform rating on Check Point Software (NASDAQ:CHKP) and raises the price target from $140 to $142.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:06 pm

COEP

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) announced that research demonstrating the potential of the SNAP-CAR T-cell platform to target multiple antigens, including HER2 and CD20, will be presented at the Society for Immunotherapy of Cancer's 38th Annual Meeting (SITC 2023). The research suggests that SNAP-CAR can potentially enable the development of T-cell therapies that can be tuned by adaptor dose and targeted toward multiple antigens, potentially avoiding toxicities and relapse due to antigen loss.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:05 pm